More information about POXEL

At Poxel, we are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. We believe that targeting cellular energy for the treatment of type 2 diabetes is a key focus and we believe that it represents the root of the disease. Imeglimin, our lead program targets mitochondrial dysfunction and PXL770 targets adenosine monophosphate-activated protein kinase (AMPK). Our Core Strengths - Leading diabetes and metabolic disease clinical development expertise - Developing first-in-class type 2 diabetes treatments for a large addressable market with significant unmet needs - Our lead clinical candidate Imeglimin features an innovative dual mechanism of action - Imeglimin in the U.S., EU and Japan met its primary and secondary endpoints in Phase 2 and is Phase 3-ready - Imeglimin in Japan offers a unique opportunity for value creation in the second largest market for diabetes and is on track to enter Phase 3 in the fourth quarter of 2017 - Our clinical candidate PXL770 represents a novel direct AMPK activator - Imeglimin and PXL770 are unencumbered programs and offer a compelling value proposition Our innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for type 2 diabetes and other metabolic diseases. Our lead clinical candidate, Imeglimin, has completed Phase 2 clinical development for type 2 diabetes in the United States, Europe and Japan, completing 8 Phase 2 clinical trials.